Journal Article

The Impact COVID-19 Infection on Cancer Patients: A Tertiary Cancer Center Experience in Jordan

Al-rabi, Kamal, Abu Abed, Layan, Akkawi, Mohammad, Salah, Samer, Al-Qadi, Fadwa, Halahleh, Khalid, Sughayer, Maher, Ababneh, Hazim, Tafesh, Lana, Ma'koseh, Mohammad, Al-Ibraheem, Akram

2023

Overview

Cancer patients are at higher risk of serious complications of COVID-19. Few studies evaluated the impact of COVID-19 on cancer patients in low- and middle-income countries. Our study aims to evaluate the outcomes of COVID-19 infection in cancer patients treated at our institution.  Methods: Medical records of patients with a positive COVID-19 polymerase chain reaction (PCR) between April 2020 and October 2020 were reviewed. Fisher's exact test and logistic regression analysis were employed to correlate various variables with mortality. Survival estimates were generated using the Kaplan-Meier method. A total of 317 patients were included, with a median age was 55 years (range: 19-88). 82 (25.9%) had hematological neoplasms while the remainder had solid cancers. At the time of infection, 220 (69.4%) had active cancer, and 99 (31.2%) had received systemic anticancer treatment (SACT) within four weeks. Hospitalization was required for 101 (31.8%), 17 (5.3%) were admitted to the ICU and 50 (15.8%) died. Among patients with active cancer, SACT was delayed or discontinued in 140 (63.6%) patients.  In the entire patient cohort, low albumin (p=<0.001) and leucocytosis (p=<0.001) correlated with mortality within six months of COVID-19 infection. The six-month mortality rate in patients with active cancer was significantly higher in patients with hypertension (p=0.024), no recent SACT (0.017), hematological cancer (p=0.029), low albumin (p=<0.001), leucocytosis (p=0.002) and lymphocyte count of less than 500/µL (p=0.004). Recent chemotherapy was associated with better 6-month survival rates (78.8% vs 89.9%, p=0.012) in patients with active cancer, patients with solid cancers (95.9% vs 82.2%, p=0.006) and was non-inferior in patient with hematological neoplasms (72% vs 65.4%, p=0.519).  Conclusion: COVID-19 infection in our cancer patients was associated with significant morbidity and mortality and adversely affected their treatment. The decision to delay or discontinue SACT should be individualized, considering other risk factors for mortality.

• Publisher: Springer Nature B.V,Cureus
• Subject: Age / Blood cancer / Breast cancer / Cancer therapies / Cardiovascular disease / Chemotherapy / COVID-19 / Diabetes / Gender / Hematology / Hemoglobin / Hospitalization / Hypertension / Infections / Infectious Disease / Kidney diseases / Lung cancer / Lung diseases / Lymphocytes / Lymphoma / Mortality / Multivariate analysis / Neutrophils / Oncology / Pandemics / Patients / Severe acute respiratory syndrome coronavirus 2 / Tumors / Variables